ArticleBlood neoplasia2026
Survival benefit of chemoradiotherapy in limited-stage mantle cell lymphoma: a National Cancer Database analysis.
Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited-stage mantle cell lymphoma (MCL) is rare, and optimal management remains undefined because of limited representation in clinical studies. We conducted a large population-based analysis using the National Cancer Database to evaluate overall survival (OS) in patients with Ann Arbor stage I to II MCL diagnosed between 2004 and 2015. Initial treatment was categorized to chemotherapy alone, radiotherapy (RT) alone, or combined chemotherapy plus RT (Chemo+RT), and outcomes were further stratified by stage and era of diagnosis (2004-2009 vs 2010-2015) to account for advances in systemic therapy, such as the adoption of bendamustine-rituximab for frontline therapy and the availability of Bruton tyrosine kinase inhibitors for relapsed disease. Among 2428 patients included, median OS for the entire cohort was 8.1 years. Chemo+RT was associated with superior OS compared with chemotherapy alone or RT alone (median OS, 11.2 vs 7.4 vs 8.0 years, respectively;
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.